Bristol Myers reports positive Phase 2 QUINTESSENTIAL myeloma results
Bristol Myers Squibb announced positive Phase 2 registrational QUINTESSENTIAL trial results for arlocabtagene autoleucel (arlo-cel; BMS-986393) in adult patients with quadruple-class exposed relapsed and refractory multiple myeloma (RRMM).
Bristol Myers Squibb NYSE:BMY said today that Phase 2 results from the registrational QUINTESSENTIAL trial of arlocabtagene autoleucel (arlo-cel; BMS-986393) were positive in adult patients with quadruple-class exposed relapsed and refractory multiple myeloma (RRMM). Arlo-cel is described as a potential first-in-cla…